Sept 24 (Reuters) - Acadia Pharmaceuticals ( ACAD ) said

on Wednesday that its experimental therapy to treat a rare

metabolic condition failed to meet the main goal in a late-stage

study.

The company was testing the treatment, called ACP-101, to

treat hyperphagia, or feelings of intense and persistent hunger,

in patients with a genetic disorder called Prader-Willi

syndrome.

The treatment did not demonstrate a statistically

significant improvement over placebo on the study's main goal

that measured changes in hyperphagia in patients.